As of Dec 02
| -2.85 / -0.76%|
The 22 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 448.00, with a high estimate of 626.00 and a low estimate of 300.00. The median estimate represents a +20.20% increase from the last price of 372.71.
The current consensus among 27 polled investment analysts is to Hold stock in Regeneron Pharmaceuticals. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.